Crossmark

Patient-reported oral adverse events during cancer chemotherapy: longitudinal evaluation using patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) and concordance with clinician assessments

Crossref DOI link: https://doi.org/10.1007/s00520-025-10126-3

Published Online: 2025-11-13

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sakai, Yuki https://orcid.org/0009-0006-5198-7257
Katsura, Kouji https://orcid.org/0000-0002-7341-4840
Kanemitsu, Yoshitomi https://orcid.org/0000-0002-0209-224X
Kotake, Masaaki https://orcid.org/0009-0008-5433-4854
Toyama, Akira https://orcid.org/0000-0002-4802-2984
License Information

Text and Data Mining valid from 2025-11-13

Version of Record valid from 2025-11-13
More Information

Article History

Received: 25 June 2025

Accepted: 29 October 2025

First Online: 13 November 2025

Declarations

:

: This study was approved by the Ethics Committee of the Niigata University School of Medicine (approval number: 2023-0315). As this was a retrospective observational study using existing medical records, we employed an opt-out method for obtaining consent in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan. Information about the study was publicly disclosed on the Niigata University School of Medicine website, providing participants with the opportunity to refuse participation. The study was conducted in accordance with the Declaration of Helsinki.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below